New drooling treatment shows promise in Year-Long study
NCT ID NCT02610868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of repeated MYOBLOC injections over one year in 187 adults with troublesome drooling caused by conditions like Parkinson's disease, stroke, or ALS. Participants received up to four treatment sessions, and researchers tracked side effects and changes in saliva flow. The goal was to see if this botulinum toxin treatment could safely reduce drooling over the long term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIALORRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Phoenix, Arizona, 85013, United States
-
Study site
Scottsdale, Arizona, 85258, United States
-
Study site
Scottsdale, Arizona, 85259, United States
-
Study site
Loma Linda, California, 92354, United States
-
Study site
Los Angeles, California, 90033, United States
-
Study site
Aurora, Colorado, 80045, United States
-
Study site
Atlantis, Florida, 33462, United States
-
Study site
Boca Raton, Florida, 33486, United States
-
Study site
Orlando, Florida, 32806, United States
-
Study site
Port Charlotte, Florida, 33980, United States
-
Study site
Atlanta, Georgia, 30329, United States
-
Study site
Kansas City, Kansas, 66160, United States
-
Study site
Overland Park, Kansas, 66211, United States
-
Study site
Elkridge, Maryland, 21075, United States
-
Study site
Farmington Hills, Michigan, 48334, United States
-
Study site
St Louis, Missouri, 63110, United States
-
Study site
Las Vegas, Nevada, 89145, United States
-
Study site
Edison, New Jersey, 08818, United States
-
Study site
Centerville, Ohio, 45459, United States
-
Study site
Tulsa, Oklahoma, 74136, United States
-
Study site
Greenville, South Carolina, 29615, United States
-
Study site
Cordova, Tennessee, 38018, United States
-
Study site
San Antonio, Texas, 78229, United States
-
Study site
Kirkland, Washington, 98034, United States
-
Study site
Spokane, Washington, 99202, United States
-
Study site
Tacoma, Washington, 98409, United States
-
Study site
Grodno, 230017, Belarus
-
Study site
Dnipropetrovsk, 49027, Ukraine
-
Study site
Ivano-Frankivsk, 76008, Ukraine
-
Study site
Kharkiv, 61068, Ukraine
-
Study site
Lviv, 79010, Ukraine
-
Study site
Odesa, 65025, Ukraine
-
Study site
Rivne, 33010, Ukraine
-
Study site
Uzhhorod, 88018, Ukraine
-
Study site
Zaporizhzhya, 69600, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.